Cardiac magnetic resonance (CMR) imaging is widely used in various medical fields related to cardiovascular diseases. Rapid technological innovations in magnetic resonance imaging in recent times have resulted in the development of new techniques for CMR imaging. T1 and T2 image mapping sequences enable the direct quantification of T1, T2, and extracellular volume fraction (ECV) values of the myocardium, leading to the progressive integration of these sequences into routine CMR settings. Currently, T1, T2, and ECV values are being recognized as not only robust biomarkers for diagnosis of cardiomyopathies, but also predictive factors for treatment monitoring and prognosis. In this study, we have reviewed various T1 and T2 mapping sequence techniques and their clinical applications.
Cardiac magnetic resonance (CMR) imaging is widely used in various medical fields related to cardiovascular diseases. Rapid technological innovations in magnetic resonance imaging in recent times have resulted in the development of new techniques for CMR imaging. T1 and T2 image mapping sequences enable the direct quantification of T1, T2, and extracellular volume fraction (ECV) values of the myocardium, leading to the progressive integration of these sequences into routine CMR settings. Currently, T1, T2, and ECV values are being recognized as not only robust biomarkers for diagnosis of cardiomyopathies, but also predictive factors for treatment monitoring and prognosis. In this study, we have reviewed various T1 and T2 mapping sequence techniques and their clinical applications.
Cardiac magnetic resonance (CMR) imaging is widely used in various fields related to cardiovascular diseases (1). The main advantage of CMR is its potential for characterization of myocardial tissues. Recent technological developments have enabled T1-mapping, which allows the instant detection of myocardial abnormalities beyond the ability of detection by conventional qualitative assessment. T1 and T2 mapping CMR sequences are rapidly becoming the gold standard and have been integrated into routine CMR imaging protocols (2).The major advantage of T1 mapping sequences is their potential for quantitative objective assessment of myocardial abnormalities. Conventional signal intensity-based CMR techniques involve qualitative nonparametric sequences. Although these sequences allow semi quantitative analysis using region-of-interest (ROI) or threshold-based methods, their ability is limited to the evaluation of diffuse myocardial changes such as myocarditis or diffuse fibrosis (34). In contrast, T1 and T1 mappings are parametric quantitative sequences, which provide tissue-specific T1 and T2 values. They allow the comparison of quantified myocardial parameters with normal reference values acquired under the same scanning conditions such as scanner type, contrast agent, and scan time (5). The other advantage of T1 and T2 mapping is the simplicity of T1 and T2 map acquisition and parametric T1 and T2 value measurement. Myocardial T1 and T2 maps can be generated using the single breath-hold technique (678).T1 times can be determined either using manual or automatic ROIs or by applying automatic thresholds. Furthermore, the measurements are obtained directly on the maps, wherever they are displayed, and the use of a picture archiving and communications system is dispensable (9). Native T1, T2, and extracellular volume fraction (ECV) values are representative parameters acquired by T1 and T2 mapping CMR imaging (Fig. 1). In 2013, Moon et al. (5) documented the recommendations for T1 mapping sequence acquisition and quantification for clinical and research use, based on published data and expert consensus.
Fig. 1
Representative short-axis images of native T1, post-contrast T1 and T2, and extracellular volume fraction (ECV) maps of control subject.
Pixels in generated map represent corresponding T1, T2, and ECV values of regions of interest in myocardium or other cardiac structures. Myocardium and other cardiovascular structures each have tissue-specific T1, T2, and ECV values.
In the present study, we will review the T1 and T2 mapping parameters, a few of the available T1 and T2 mapping sequence techniques, and the clinical feasibility of T1 and T2 mapping parameters in various aspects of cardiomyopathy.
T1 and T2 Mapping Parameters
Native T1
T1 relaxation time, which is also referred to as spin-lattice or longitudinal relaxation time, is a biological magnetic resonance (MR) parameter. T1 relaxation time indicates how quickly nuclei recover towards thermodynamic equilibrium along the B0 direction. The value of T1 relaxation time depends on the rate of energy transfer from an excited proton to its surroundings. The native T1 value is a tissue-specific time constant used to distinguish different tissues. The rate of energy transfer varies according to the state of the molecular environment (e.g., molecular size, shape, viscosity, temperature, and magnetic field strength). T1 values increase with the increase in field strength (10). T1 values reported by various studies vary slightly according to the sequence used. Normal myocardial native T1 values acquired using the modified Look-Locker inversion recovery (MOLLI) MR method have been reported to be 930 ± 21 ms at 1.5 T and 1052 ± 23 ms at 3T (11). Table 1 presents the reference T1 mapping values reported by various studies according to the acquisition sequences and field strengths (Table 1). The native T1 value of the myocardium is also dependent on age and sex—men and older subjects exhibit slightly higher values than do women and younger subjects (2). Tissues generally contain water and a variety of large molecules. Since pathological processes alter the water composition or local molecular environment of tissues, they also generally alter the T1 values. Representative myocardial pathologies leading to T1 changes include diffuse myocardial fibrosis (121314), edema (151617), inflammation (18), infiltrative diseases (9) such as amyloidosis (1213), Fabry disease (FD) (19), and hemosiderosis (2021), a condition where abnormal substances are deposited in the myocardium. Native T1 is thus regarded as a promising method for the detection of myocardial abnormalities without the necessity of administration of gadolinium contrast agent.
Table 1
Reference T1 Mapping Values According to Acquisition Sequence and Field Strength
Magnetic Field (Tesla)
T1 Mapping (Ref.)
Pattern
TR (ms)
TE (ms)
FA (°)
Voxel Size (mm3)
Acceleration Imaging
Study Population
Native T1 Value (ms)
Post-Contrast T1 Value (ms)
ECV
Contrast Media
1.5T
LL (52)
-
2.2
1.1
50
2.1 × 2.2 × 8
GRAPPA = 2
14 healthy volunteers 57% male, 38 ± 10.9 years
1000.4 ± 126
984 ± 28
-
Magnevist® (Bayer) 0.14–0.2 mmoL/kg
MOLLI (52)
3(3)3(3)5
2.2
1.1
35
1.9 × 2.2 × 8
Turbo factor = 8
14 healthy volunteers 57% male, 38 ± 10.9 years
1029.4 ± 56.8
418.1 ± 70.2
-
Magnevist® (Bayer) 0.14–0.2 mmoL/kg
MOLLI (58)
Pre-contrast mapping: 5(3)3
3.1
1.5
35
1.9 × 2.5 × 8
SENSE = 2
7 healthy volunteers 57% male, 38 ± 19 years
1052 ± 41
-
~0.27
MultiHance (Bracco) 0.1 mmoL/kg
Post-contrast mapping: 4(1)3(1)2
ShMOLLI (58)
5(1)1(1)1
3.1
1.5
35
1.9 × 2.5 × 8
SENSE = 2
7 healthy volunteers 57% male, 38 ± 19 years
959 ± 56
-
~0.26
MultiHance (Bracco) 0.1 mmoL/kg
SASHA (58)
-
3.1
1.5
70
1.9 × 2.5 × 8
SENSE = 2
7 healthy volunteers 57% male, 38 ± 19 years
1202 ± 56
-
~0.18
MultiHance (Bracco) 0.1 mmoL/kg
SASHA (7)
-
2.6
1.3
70
2.5 × 1.85 × 8
GRAPPA = 2
10 healthy volunteers 60% male, 54 ± 6 years
1170 ± 9
568 ± 40
-
Magnevist® (Bayer) 0.15 mmoL/kg
MOLLI (11)
3(3)3(3)5
3.3
1.64
50
1.8 × 1.8 × 8
SENSE = 2
34 healthy volunteers 53% male, 41 ± 17 years
930 ± 21
415 ± 11
0.25 ± 0.04
Gadovist® (Bayer) 0.1, 0.15, or 0.2 mmoL/kg
ShMOLLI (2)
5(1)1(1)1
1.9–2.2
1.0–1.07
35
1.8 × 1.8 × 8.0
GRAPPA = 2
342 healthy volunteers 50% male, 11–69 years
962 ± 25
-
-
-
MOLLI (122)
3(3)3(3)5
2.8
1.2
35
2.2 × 1.4 × 8.0
GRAPPA = 2
40 healthy volunteers 50% male, 20–35 years
984 ± 28
-
-
-
3T
MOLLI (28)
3(3)3(3)5
2.6–2.7
1.0–1.1
35
1.6–1.8 × 1.6–1.8 × 8
GRAPPA = 2
60 healthy volunteers 50% male, 20–80 years
1158.7
411.2
-
Gadovist® (Bayer) 0.1, 0.15, or 0.2 mmoL/kg
MOLLI (11)
3(3)3(3)5
3.3
1.64
50
1.8 × 1.8 × 8
SENSE = 2
32 healthy volunteers 53% male, 41 ± 17 years
1052 ± 23
421 ± 13
0.26 ± 0.04
Gadovist® (Bayer) 0.1, 0.15, or 0.2 mmoL/kg
ECV = extracellular volume fraction, FA = flip angle, GRAPPA = generalized autocalibrating partially parallel acquisition, LL = Look-Locker, MOLLI = modified Look-Locker inversion recovery, SASHA = saturation recovery single shot acquisition, SENSE = sensitivity encoding for fast MRI, ShMOLLI = shortened MOLLI, TE = echo time, TR = repetition time
T2 Relaxation Time
T2 relaxation time, also referred to as spin-spin or transverse relaxation time, is another biological parameter of CMR imaging. Similar to T1 relaxation time, T2 relaxation time is also a tissue-specific time parameter used to distinguish between normal and abnormal myocardial tissues. The increase in water content of myocardial tissues is the main cause for longer T2 relaxation times. Therefore, myocardial edema is the main pathology responsible for variation in T2 values. T2 mapping sequences are useful for the detection of myocardial edema in patients with acute myocardial infarction (AMI) (22), myocarditis (2324), stress cardiomyopathy (23), sarcoidosis (25), and cardiac allograft rejection (26). Normal myocardial T2 values acquired using steady-state free precession (SSFP) MR imaging have been reported to be 52.18 ± 3.4 ms at 1.5T (27) and 45.1 ms at 3T (28).
Extracellular Volume Fraction Values
The myocardium can be divided into its cellular and extracellular or interstitial components (2930). The cellular components include cardiac muscles (involuntary striated muscle fibers), which are interconnected by intercalated discs, structural components, nuclei, sarcolemma, sarcoplasmic reticulum, and vascular and neuronal elements. The interstitial component is the complex three-dimensional extracellular space in which the cellular components of the myocardium are embedded (31); this space comprises fluid, collagen, elastin, fibrils, and other glycoproteins (32). The interstitium is a complex and dynamic environment, which is vital for normal cardiac structure and function. Interstitial extracellular space expansion is a distinctive feature of myocardial pathology and an important factor in ventricular remodeling. It could also be a potential therapeutic target (33). Myocardial fibrosis, a common pathology of end-stage heart diseases and a major independent predictor of a major adverse cardiac event (31), is the major cause of extracellular space expansion. Other pathologies such as edema and inflammation may also cause extracellular space expansion. Previously, invasive endomyocardial biopsy was the only available method for the quantification of diffuse fibrosis (33). However, currently, T1 mapping techniques have enabled the quantitative estimation of myocardial interstitial remodeling and extracellular space expansion, and they are increasingly being used in the evaluation of myocardial ECV (33). The robustness of CMR-quantified ECV quantification has been proven by several studies (343536). In a state of dynamic equilibrium with regard to contrast distribution between the blood cavity and myocardium, the partition coefficient for the two structures can be calculated from their pre and post-contrast T1 values. The myocardial ECV is derived by correcting for the hematocrit level (37). It can be calculated using the following equation:ECV = {(ΔR1 of myocardium / ΔR1 of left ventricular [LV] blood pool)} × (1 - hematocrit level), where R1 = 1 / T1 and ΔR1 = post-contrast R1 - pre-contrast R1.Post-contrast T1 values are known to vary depending on the gadolinium dosage and clearance rate, scanning time, body composition, and hematocrit levels. However, ECV is known to be a more stable and biologically significant biomarker (3839).Myocardial ECVs in healthy volunteers were reported to be similar at field strengths of 1.5T (0.25 ± 0.04) and 3T (0.26 ± 0.04) (Table 1) (40). According to the consensus recommendation of Moon et al. (5), a “bolus only” injection is sufficient for ECV measurement, while, for post-contrast T1 mapping acquisition time point, a minimum delay of 15 minutes is recommended for reaching a state of dynamic equilibrium (3441). According to a recent multi-ethnic study of atherosclerosis based on the evaluation of CMR data, although women exhibited higher ECV than men, they exhibited relatively less ECV change over time (42). In healthy subjects, ECV is known to increase slightly with age (39). It allows the quantification of diffuse myocardial pathologies and exhibits great potential for the visualization of fibrosis, edema, amyloid, iron overload, and lipids (43).
Technical Review
Evolution of the Cardiac T1 Mapping Sequence
Cardiac T1 mapping has attracted attention as an important diagnostic imaging tool. As recently as a few years ago, T1 mapping was challenging because of severe time constraints related to cardiac and respiratory motion (44). Standard inversion recovery (IR) measurement requires a long repetition time, approximately five times as long as the T1 value, in order to allow complete restoration of longitudinal magnetization (45). This measurement technique is not applicable to the heart because the breath-hold time is insufficient for calculating an accurate T1 value, especially since samples are required for at least six to ten time points along the T1 recovery curve (46). The Look-Locker (LL) sequence was introduced (47) for the measurement of T1 relaxation times at multiple time points after an initial preparation pulse. It was subsequently adapted to the MOLLI (48) sequence. In particular, the MOLLI sequence was the first to allow pixelwise T1 mapping for cardiac MR imaging. It facilitated intuitive interpretation and quantitative analysis using high-resolution T1 maps and inspired various T1 mapping methods. The recently developed saturation recovery (SR) single-shot acquisition (SASHA) and saturation pulse prepared heart-rate-independent inversion recovery techniques have been shown to outperform MOLLI (749). Several myocardial T1 mapping methods currently incorporate single breath-holding with electrocardiogram gating to freeze cardiac motion on a specific phase, thus eliminating tissue motion, and employ longitudinal magnetization preparation pulses such as inversion or SR pulses to yield a heavy T1 weighting. Active T1 mapping development is progressing towards achieving improved accuracy and precision in as short a scan time as possible. We will briefly review representative T1 mapping methods including the LL, MOLLI, shortened MOLLI (ShMOLLI), and SASHA methods to clarify the basic concepts and limitations of each technique. Although this review mainly focuses on T1 mapping methods, we will briefly address one of the T2 mapping methods as well as the parameters for T1 and T2 mapping sequences (Table 2) to facilitate understanding.
Table 2
Imaging Parameters of T1 and T2 Mapping Sequences
Sequence
T1 Mapping (Ref.)
T2 Mapping (Ref.)
MOLLI (7)
MOLLI (10)
ShMOLLI (5)
SASHA (6)
T2p-SSFP (5)
T2p-SSFP (59)
Magnetic field
1.5T
3T
1.5T and 3T
1.5T
1.5T
3T
Preparation
Non-selective inversion recovery
Non-selective inversion recovery
Non-selective inversion recovery
Non-selective saturation recovery
Non-selective T2-preparation
Non-selective T2-preparation
Flip angle
35°
35°
35°
70°
40°
70°
Image matrix
192 × 128
256 × 180
144 × 192
108 × 192
96 × 160
176 × 144
Acquisition
Single shot SSFP
Single shot SSFP
Single shot SSFP
Single shot SSFP
Single shot SSFP
Single shot SSFP
Bandwidth (Hz/pixel)
1090
1045–1028
1090
1090
1488
1093
Parallel acquisition
SENSE/2
GRAPPA/2
GRAPPA/2
GRAPPA/2
GRAPPA/2
GRAPPA/2
Slice thickness TI increment
8 mm
6 mm
8 mm
8 mm
8 mm
6 mm
TI increment
80 ms
-
80 ms
76 ms
NA
NA
Acquisition window
202 ms
-
206 ms
175 ms
-
-
T2-prep time
NA
NA
NA
NA
0, 24, 55 (ms)
0, 24, 55 (ms)
Inversion/ saturation
3
3
3
9
NA
NA
Acquisition heartbeats
3, 3, 5
3, 3, 5
5, 1, 1
10
3
3
Recovery heartbeats
3, 3, 1
3, 3, 1
1, 1, 1
0
4
4
Acquisition time
17 RR
17 RR
9 RR
10 RR
7 RR
7 RR
TI/saturation time
100 ms
91 ms
100 ms
119–885 ms
NA
NA
Echo spacing
2.5 ms
2.6–2.7 ms
2.14 ms
2.6 ms
2.6 ms
2.4 ms
GRAPPA = generalized autocalibrating partially parallel acquisition, MOLLI = modified Look-Locker inversion recovery, NA = not applicable, RR = the time inverval between two consecutive R waves in the electrocardiogram, SASHA = saturation recovery single shot acquisition, SENSE = sensitivity encoding for fast MRI, ShMOLLI = shortened MOLLI, SSFP = steady-state free precession, TI = inversion time
Look-Locker Sequence
The LL sequence, also known as the “inversion time (TI) scout” sequence, has been broadly implemented in most MR imaging protocols. In 1970, Look and Locker (47) proposed an efficient method for the measurement of T1 time using a continuous and periodic train of radiofrequency (RF) pulses after the inversion pulse. Conditional upon a number of factors, including the type of readout sequence and tissue characteristics, longitudinal magnetization recovers to steady-state quicker than undisturbed equilibrium magnetization (50), as shown in Figure 2.
Fig. 2
Apparent T1* and true T1 recovery.
Comparison of longitudinal magnetization using standard inversion recovery and Look–Locker (LL) T1 mapping methods. With LL method, T1 recovery to steady state is achieved more rapidly and often denoted as apparent T1 (T1*). IR = inversion recovery, RF = radiofrequency
For this reason, the LL sequence measures the apparent recovery time (referred to as T1*) instead of “true T1”, the actual longitudinal recovery time. T1* is usually less than the true T1.The apparent recovery curve follows a three-parameter exponential recovery model, S(t) = A - B exp (-t / T1*), where S(t) is the signal intensity at TI t. The values of A, B, and T1* are estimated by curve-fitting using the three-parameter model. T1* can be corrected by applying an LL correction: T1 = T1* (B / A-1) (50).The LL method acquires approximately 20 images with a variety of readout sequences such as the SSFP and fast low-angle shot sequences throughout the cardiac cycle, without regard for gating to a specific phase in order to mitigate cardiac motion during a single long breath-hold (51). Therefore, it would be difficult to create a pixel-based T1 map from an LL sequence because of the variability of heart rate (HR) (52) as well as the partial volume effect (53) resulting from physiological motion and misregistration.
Modified Look-Locker Inversion Recovery Sequence
The MOLLI technique was designed to overcome the limitations of the LL sequence. It was first brought into widespread use for myocardial T1 mapping. The MOLLI technique is used to acquire IR-weighted images at different prescribed TIs using single-slice, single-shot readouts throughout one breath-hold within a cardiac cycle in a specific phase, following which the images are sorted into a single data set according to consecutive TIs (48). The original MOLLI was a 3(3)3(3)5 protocol. This protocol code indicates the number of inversion pulses and samples and the recovery period—the unbracketed numbers are the numbers of images acquired after the inversion pulse, and the bracketed ones are the numbers of RR intervals for T1 recovery. Figure 3 presents a simple example of a MOLLI sequence with a 5(3)3 protocol (54). This protocol involves two inversion pulses and a recovery period of three RR intervals, with five or three images acquired after the first and second inversions. To obtain a pixel-wise T1 map, the acquired images are sorted according to the TI, following which, three-parameter model fitting, including LL correction, is performed as described for the LL method. Although MOLLI uses a gated-SSFP readout, the three-parameter model fitting and LL correction are adequately effective when using a low flip angle on the readout. To achieve a superior signal-to-noise ratio and reproducibility, a balanced SSFP readout is employed along with aggressive parallel imaging techniques, thus providing a narrow acquisition window and minimizing myocardial misregistration (44). The sensitivity of MOLLI towards HR can be mitigated by employing a single inversion or increasing the time between inversions to ensure a more complete recovery (104054).
Fig. 3
Modified Look–Locker inversion recovery (MOLLI) with 5(3)3 protocol.
MOLLI method features several modifications intended to improve accuracy and precision. This protocol employs two inversions and acquires three or five images after first and second inversions, with three RR intervals for T1 recovery. Images are sorted according to inversion time to perform pixel-wise three-parameter fitting. ECG = electrocardiogram, RR = the time interval between two consecutive R waves in the electrocardiogram, SSFP = steady-state free precession
The ShMOLLI sequence is one modification of the MOLLI sequence. It provides a faster acquisition time within a short breath-hold duration of only nine heartbeats, in contrast to MOLLI, which requires a 17-heartbeat duration and is less HR-dependent (6).The ShMOLLI sequence is very similar to MOLLI. However, the former does not require the full recovery of longitudinal magnetization because of the conditional data analysis algorithm, as shown in Figure 4. During the process of T1 estimation, the conditional data analysis algorithm distinguishes a set of samples according to the T1 times using curve-fitting errors. In regions of long T1, the set of samples from the first inversion is fitted using the three-parameter model, while the samples from the first and second inversions are fitted for short T1. For very short T1, the samples from all inversions are used. ShMOLLI with seven samples might exhibit increased variability because of the insufficient number of images for T1 curve-fitting. Reduced precision with ShMOLLI is considered a trade-off for reduced scan time and breath-hold requirement.
ShMOLLI method employs conditional analysis algorithm that can distinguish between short and long T1 values using curve-fitting errors and, therefore, features shorter scan time than original MOLLI. Long T1 samples use set of samples from first inversion to estimate T1, whereas short T1 samples use set of samples from all inversions. ECG = electrocardiogram, SSFP = steady-state free precession, TI = Inversion time
Saturation recovery methods for T1 mapping have begun to attract attention as surrogates for IR methods. The SR pulse non-selectively saturates the longitudinal magnetization to zero, independent of previous acquisitions. Recovery periods are, therefore, not required between successive saturation pulses because recovery always begins from a saturated state. The best-known T1 method is SASHA (7).Saturation recovery single-shot acquisition protocols involve the acquisition of ten single-shot balanced steady-state free precession (bSSFP) images over consecutive heartbeats. The first image is initially acquired without any saturation preparation, using equilibrium magnetization as an anchor point for curve-fitting, and the remaining images are acquired after a saturation pulse with a different saturation delay over the RR interval (7), as shown in Figure 5. The accuracy and precision of the T1 map varies depending on the use of a two or three-parameter fitting model. Two-parameter model fitting, defined by S(t) = A (1 - exp [-t / T1]), greatly reduces variability at the cost of systematic bias resulting from the assumption of ideal saturation efficiency. In other words, it can improve the precision of the T1 map, but at the cost of accuracy. On the other hand, the three-parameter model, defined by S(t) = A - Bexp (-t / T1), is unaffected by any imperfection in the saturation RF pulse; it is, therefore, highly accurate but sensitive to noise. In the fitting model, A indicates the scaling factor, and B indicates the saturation efficiency (1055).
Fig. 5
Saturation recovery single shot (SASHA).
SASHA method acquires data at successive heartbeats by saturation recovery over RR-interval at different saturation times, using initial unperturbed image. Accuracy and precision depend on choice of two- or three-parameter fitting model. ECG = electrocardiogram, RR = the time inverval between two consecutive R waves in the electrocardiogram
Recent improvements to the SASHA method include the application of a variable readout flip angle, two-parameter fitting, and high-performance saturation pulses, all of which have remarkably improved its accuracy and precision (56). To improve the saturation efficiency, an adiabatic or optimized RF pulse is needed to more completely saturate the residual longitudinal magnetization of the myocardium in the B0 and B1 field variations (57).
Accuracy and Precision of T1 Mapping
In T1 mapping techniques, the accuracy and precision of the T1 map is influenced by whether or not magnetization preparation pulses are used between IR and SR pulses.The IR pulse inverts the longitudinal magnetization vectors from +M0 to −M0. Afterwards, the inverted vectors begin their recovery from −M0 to +M0. This wide dynamic range can help acquire various IR-weighted images and improve the precision of T1 mapping. In contrast, the SR pulse is used for nullifying the longitudinal magnetization vectors by followed a spoiling gradient pulse. The initial part of T1 recovery has poor signal-to-noise ratio because of insufficient T1 recovery. The precision of T1 maps obtained from SR-weighted images is lower compared to that obtained with the IR pulse (1058).In terms of accuracy of T1 maps, SR pulse sequences can produce T1 maps of excellent accuracy, because the nullifying of the SR pulse relieves the effect of previous longitudinal magnetization, thus rendering the T1 map less sensitive to T2-dependence, magnetization transfer effect, and dependence on saturation efficiency. However, with IR pulse sequences, the accuracy of the T1 map is largely influenced by the degree of restoration of inverted magnetization vectors before the succeeding IR pulse. Other factors affecting the accuracy of T1 maps with IR pulse sequences are T2-dependence, magnetization transfer effect, and dependence on inversion efficiency (1058).
Myocardial T2 Mapping Technique
T2 mapping is another promising tissue characterization technique. Two types of T2 mapping sequences are used in cardiac MR imaging—dark-blood turbo spin-echo (TSE) and bright-blood T2-preparation pulse-based sequences. TSE-based T2 mapping has some limitations, including the appearance of ghosting artifacts from blood flow, which result in an increase in the appearance of bright subendocardial rims, and through-plane motion, which results in signal loss and can significantly limit the clinical applicability of this method (515960). In contrast, T2-preparation-based methods are less sensitive to TSE-associated artifacts (5961), and a T2-decay curve can be created using spin-spin relaxation to adjust the T2 preparation time. This method involves two steps— a T2-preparation module and a rapid imaging sequence that includes bSSFP or rapid gradient echo sequence, as illustrated in Figure 6. The T2-preparation module comprises non-selective 90° and 180° pulses to create spin-spin relaxation between two 90° pulses. After preparation, the magnitude of longitudinal magnetization depends on the degree of T2 decay. This magnitude can be adjusted by varying the duration of the T2-preparation module. The imaging sequence, either a balanced SSFP or gradient echo sequence, is run immediately after preparation. A T2 map is generated by two-parameter model fitting, defined by S(t) = A exp (-t / T2), where S indicates the signal intensity, A, the scaling factor, and t, the T2 preparation time.
Fig. 6
T2 mapping scheme with T2 preparation modules.
T2-weighted images are acquired with different T2 preparation times, with same trigger delay time (TD), to ensure same cardiac cycle phase during breath-hold. T1 recovery time is needed to allow complete T1 recovery. This preparation module employs 90° and 180° pulses to create T2 decay via spin-spin relaxation during T2 preparation time. Module concludes with spoiler gradient for removal of residual transverse magnetization. ECG = electrocardiogram, GRE = gradient echo, SSFP = steady-state free precession
Clinical Applications of T1 and T2 Mapping Sequences
Non-Ischemic Cardiomyopathy
Dilated Cardiomyopathy
Dilated cardiomyopathy (DCM) is a cardiac muscle disease with unknown or variable etiology. It is characterized by ventricular dilation and impaired systolic function without evidence of other loading conditions (6263). Diffuse myocardial fibrosis is a fundamental factor for cardiac remodeling (36264). The degree of myocardial fibrosis is a prognostic factor associated with the progression of cardiac dysfunction (65). Late gadolinium enhancement (LGE) is a powerful imaging tool that can detect the presence, location, and extent of myocardial fibrosis (66). In DCM, mid-wall fibrosis, determined by LGE, is predictive of the combined endpoint of an adverse cardiac outcome (67686970). However, LGE often fails to detect diffuse fibrosis in the absence of normal myocardium, since the detection of fibrotic myocardium on LGE images is based on the difference in signal intensity between fibrotic and normal myocardium (3). In fact, many patients with DCM do not exhibit myocardial LGE (36467). However, patients with LGE-negative myocardium with a normal appearance have been reported to exhibit significantly higher native T1 and ECV values than normal control patients (Fig. 7) (1464). In patients with DCM, native T1 and ECV values are known to be significantly higher and post-contrast T1 values are known to be lower compared to those of control subjects (147172). In addition, patients with DCM also exhibit increased T2 values (737475). Native T1 imaging can help differentiate between normal and abnormal myocardia with a high level of diagnostic accuracy (71). ECV, which reflects the myocardial collagen content in patients with DCM, is also useful (76). Native T1 and ECV values correlate with LV functional parameters (6473) such as LV ejection fraction, global strain, and other biomarkers (14). Additionally, ECV can detect diffuse subclinical myocardial abnormalities even in cases of early-stage DCM (7677). The increase in T2 signal is possibly due to myocardial edema consequent to injury and inflammation related to the process of cardiomyopathy (7578). Recently, native T1 and ECV values were reported to be independent prognostic factors of adverse clinical outcome in patients with DCM (377980).
Fig. 7
T1 mapping in dilated cardiomyopathy (DCM).
DCM is
characterized by ventricular dilation and systolic dysfunction without other loading conditions. Approximately 30% of patients with DCM exhibit mid-wall late gadolinium enhancement (LGE) in regions that do not correspond to coronary artery territories. This imaging characteristic is known to be prognostic factor for DCM. However, many patients do not exhibit LGE—they usually present with increased native T1 and extracellular volume fraction values in areas without LGE. T1 mapping can detect diffuse myocardial abnormalities in areas that appear normal on LGE sequences.
Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy (HCMP) is the most common heritable myocardial disease. It is caused by mutations in genes that encode sarcomeric proteins (81). The disease is diagnosed morphologically and defined by the presence of a hypertrophic, non-dilated LV in the absence of another cause of LV hypertrophy (LVH) (63). Myocardial fibrosis is also a hallmark of HCMP (82). Cardiac MR imaging is useful for the evaluation of myocardial morphology as well as the extent of myocardial fibrosis in patients with HCMP. Significant increases in native T1 and ECV values are observed in regions affected by HCMP. In patients with HCMP, T1 mapping is useful for detecting myocardial fibrosis while overcoming the limitations of LGE (Fig. 8). Native T1 sequences can depict the presence and pattern of myocardial fibrosis even in fibrotic areas that go undetected by LGE (1483). In addition, native T1 values have been found to correlate with disease severity and increase along with increase in wall thickness in HCMP (14). Post-contrast T1 values, which have been correlated with diastolic dysfunction, are significantly low in patients with HCMP because of diffuse interstitial fibrosis (84). In patients with HCMP, the ECV values have also been found to correlate well with the collagen volume fraction. Previous studies have suggested that ECV could be a potential biomarker of HCMP, which could help distinguish between groups with and without sarcomere-related gene mutations (85).
Fig. 8
T1 mapping in hypertrophic cardiomyopathy (HCMP).
HCMP is cardiac muscle disease characterized by abnormal left ventricle hypertrophy (LVH) in absence of another cause of LVH. Multifocal late gadolinium enhancement (LGE) is usually observed in hypertrophied muscles. T1 mapping can detect myocardial abnormalities in areas that do not exhibit LGE.
Fabry Disease
Fabry disease is an X-linked glycosphingolipid storage disorder caused by mutation of the gene that encodes alpha-galactosidase, resulting in deficient enzyme activity (86).The most common cardiac manifestation of FD is LVH, followed by conduction disorders, valve dysfunction, and arrhythmias, resulting from the accumulation of globotriaosylceramide in cardiomyocytes, valves, and the conduction system (86). It is important to differentiate FD from other myopathies, such as HCMP, that can cause LVH. Notably, 50% of patients with FD exhibit the characteristic feature of LGE on the inferolateral LV wall (87).In addition to the evaluation of LGE, T1 mapping is a useful complementary tool for the evaluation of cardiac involvement in FD (Fig. 9). Decreased T1 value is a distinctive feature of myocardial involvement in FD, and it is especially significant in the LV septum.
Fig. 9
T1 mapping in Fabry disease (FD).
Left ventricle hypertrophy and late gadolinium enhancement (LGE) of inferolateral left ventricle wall are characteristic features of FD. However, only 50% of patients with FD exhibit LGE. In T1 mapping, decrease in septal native T1 value is characteristic feature that distinguishes FD from other cardiomyopathies.
This phenomenon occurs because the presence of glycosphingolipids in myocytes causes a reduction in the T1 value. A previous study demonstrated that the decrease in the septal native T1 value is a characteristic feature that can help distinguish FD from other cardiomyopathies (77). Reduction in native T1 value prior to the onset of LVH can be an early marker of FD and has been correlated with diastolic and systolic dysfunction (88). In contrast to other diseases, FD does not cause variations in the ECV (89).
Amyloidosis
Amyloidosis is a disease characterized by the deposition of insoluble misfolded protein aggregates with a characteristic β-sheet structure in tissues throughout the body (9091). Cardiac involvement is common with the immunoglobulin light chain (AL) and transthyretin types of amyloidosis, and it is associated with poor prognosis (92), particularly in the AL type of the disease (9394). Cardiac amyloidosis, histologically characterized by infiltration and expansion of the interstitial space by amyloid proteins, is usually diagnosed by an endomyocardial biopsy (95). The appearance of global, circumferential subendocardial LGE with distribution in non-coronary arterial regions is a hallmark of cardiac involvement in amyloidosis. However, characteristic LGE patterns appear late in the disease course and do not always occur (12). T1 mapping is a useful noninvasive method for the diagnosis of cardiac amyloidosis. Marked increases in native T1 and ECV values are distinguishing features of cardiac amyloidosis (Fig. 10) (9697). The use of gadolinium contrast agent is relatively contraindicated in cases of severe renal failure, which is common in patients with systemic AL amyloidosis (98). Therefore, native T1 is a useful tool for the diagnosis of cardiac amyloidosis. In a previous study, Karamitsos et al. (12) proved that native T1 value is reflective of disease severity and correlates well with the indices of systolic and diastolic dysfunction. Native T1 is useful for not only diagnosis, but also quantification of the amyloidosis burden and monitoring of disease progression (99100). In amyloidosis, ECV is also a potentially useful parameter that enables direct measurement of the amyloid burden and serves as an early marker for diagnosis, disease monitoring, and prognosis. In a recent study, Banypersad et al. (99) demonstrated that native T1 values > 1044 ms and ECV values > 45% were associated with hazard ratios for death of 3.84 (95% confidence interval [CI], 1.53–9.61) and 5.39 (95% CI, 1.24–23.4), respectively. Therefore, measurement of native myocardial T1 and ECV values facilitates the risk stratification of patients with cardiac amyloidosis. However, T2 values do not exhibit significant changes with this condition and, therefore, would not provide much diagnostic assistance (101).
Fig. 10
T1 and T2 mapping in amyloidosis.
Global, circumferential, subendocardial late gadolinium enhancement (LGE) with distribution in non-coronary arterial territory is hallmark of amyloidosis. However, characteristic LGE patterns do not always occur. In patients with amyloidosis, marked elevations in native T1 and extracellular volume fraction values are characteristic imaging features, which do not overlap with those of other diseases. However, T2 values are not increased in patients with amyloidosis.
Myocarditis
Myocarditis is an acute or chronic inflammatory process of the myocardium caused by various toxins, drugs, or infectious agents (63). Diagnosis of myocarditis is clinically challenging because its clinical symptoms are nonspecific and similar to those of other diseases such as the acute coronary syndrome. Approximately 75% of patients with acute chest pain and elevated serum troponin levels at presentation receive a diagnosis of acute myocarditis (102). However, such diagnoses were often made on a clinical basis because of the lack of a reliable noninvasive test (103). The LGE pattern associated with myocarditis is predominantly subepicardial and mid-wall (84.4%) in nature and localized most frequently to the lateral and inferior walls (104). However, LGE in myocarditis is often subtle. T1-mapping CMR imaging can be a useful noninvasive tool for the diagnosis of myocarditis. In particular, non-contrast mapping parameters such as T1 and T2 values are useful for the diagnosis of the disease (Fig. 11). In patients with myocarditis, native T1 values are significantly elevated as a result of the pathological processes of myocardial inflammation and edema (418105). Native T1 mapping imaging is superior to T2-weighted imaging and LGE and provides a high level of diagnostic accuracy and high positive and negative predictive values (18104). Native T1 imaging can detect myocardial abnormalities to a greater extent than T2-weighted imaging and LGE. The authors of a previous study suggested that native T1 imaging could discriminate between the acute and convalescent stages of myocarditis (18). The values of ECV also increase in patients with acute myocarditis. Radunski et al. (4) evaluated the accuracy of T1 mapping parameters in 104 patients with myocarditis. Quantification of ECV yielded the best diagnostic accuracy among all single CMR parameters including native T1 and post-contrast T1 and T2 values, ECV, and T2-weighted ratio. However, in another study, the diagnostic accuracy of ECV for myocarditis was not found to be superior to that of native T1 mapping (102106). Myocardial T2 mapping is another non-contrast quantitative imaging technique used for the evaluation of myocardial edema in patients with acute myocarditis, without the limitations associated with T2-weighted imaging (23). T2 mapping enables objective quantification of myocardial edema and is less sensitive to motion artifacts, surface-coil inhomogeneity, and subendocardial blood flow (22). A recent study found that myocardial T2 values are useful for differentiating acute myocarditis from recent-onset heart failure, where the native T1 and ECV values both exhibit an increase (107).
Fig. 11
T1 and T2 mapping in myocarditis.
Late gadolinium enhancement (LGE) pattern in myocarditis is usually observed on lateral inferior wall of left ventricle, with subepicardial and mid-wall distribution. Non-contrast mapping parameters and T1 and T2 values are useful for diagnosis of myocarditis.
Ischemic Cardiomyopathy
Acute Myocardial Infarction
Myocardial infarction (MI) is defined by myocardial cell death due to ischemic insult. It is most commonly caused by coronary artery disease (108). MR imaging is useful in both diagnosis and risk stratification of AMI, based on the evaluation of infarct tissue (size, location, and transmurality), area at risk (AAR), microvascular obstruction (MVO), and hemorrhage. Historically, LGE has been the gold standard for the evaluation of infarcted myocardium, with several studies having validated its efficacy (109), and the black-blood T2-weighted IR technique is widely used for the detection of edema (110). However, T1 and T2 mapping techniques are emerging as useful tools for the evaluation of AMI.Native T1 imaging with an appropriate cut-off value is useful for the highly accurate detection of AMI. Native T1 imaging can detect acute myocardial edema because the free water content prolongs both T1 and T2 values (17). Native T1 imaging and T2 mapping provide similar quantitative results in the determination of AAR after AMI (15111). Native T1 mapping can differentiate MVO in infarcted myocardium; it is characterized by T1 values higher compared to those of remote myocardium but lower compared to those of infarcted myocardium (16112). T1 mapping can also provide information regarding the degree and severity of myocardial damage. Dall'Armellina et al. (112) reported a significant relationship between non-contrast T1 mapping and the degree of myocardial damage assessed by means of LGE or T2-weighted imaging and noted that T1 values could predict functional recovery after AMI. In patients with MI, native T1 imaging can detect intramyocardial hemorrhage, which exhibits a T1 shortening effect (21). Quantitative T2 mapping reliably identifies myocardial edema without the limitations associated with T2-weighted short tau IR imaging (22). For the evaluation of AAR, T2 mapping sequences exhibit good agreement with the AAR of a microsphere (15). In AMI, post-contrast T1 mapping can provide useful information regarding the size of the infarcted myocardium, which is evaluated on the basis of T1 shortening in the infarcted myocardium (16).Evaluation of ECV by MR imaging provides a more stable measurement of the degree of fibrosis in both of infarcted and non-infarcted myocardium (113), which might be linked to adverse remodeling in cases of AMI (114).
Chronic Myocardial Infarction
In chronic MI (CMI), MR imaging plays useful roles in both diagnosis and risk stratification based on the evaluation of edema, scar size, complications, and LV remodeling. As is the case in AMI, LGE is the gold standard for the evaluation of infarcted myocardium in CMI (108). However, mapping techniques can provide valuable information regarding CMI. Native T1 and T2 mapping can differentiate chronic and acute MI based on the absence of myocardial edema (16). Myocardial edema resolves within 6 months after an acute insult. Given the very low T1 value of fatty tissue, native T1 mapping can detect areas of lipomatous metaplasia in CMI (115). Messroghli et al. (16) reported that pre-contrast T1 values lack accuracy with regard to CMI delineation. However, Kali et al. (116) reported that native T1 values could reliably characterize CMI during threshold-based detection at 3T. Scar size can be evaluated by T1 mapping and ECV. The post-contrast T1 mapping and ECV parameters allow the accurate detection of CMI based on an ECV cut-off value of 42% (117). Agreement between the infarct sizes measured by T1 mapping and delayed gadolinium imaging was higher for chronic infarcts than acute infarcts (16).
Other Cardiomyopathies
T1 and T2 mapping techniques are also useful for the diagnosis and management of other cardiomyopathies. T1 mapping is useful for the detection of subclinical myocardial changes, which are common in patients with autoimmune diseases such as systemic lupus erythematosus (118), systemic sclerosis (119), and rheumatoid arthritis (120). In patients with muscular dystrophies such as Duchenne and Becker muscular dystrophy, T1 mapping enables the early detection of cardiac involvement (121). Myocardial iron overload is characterized by a decrease in T1 values. T1 mapping is, therefore, useful for the quantification of cardiac iron (20). T2 mapping is useful in patients with cardiac transplants. In a pilot study, Usman et al. (26) demonstrated that quantitative T2 mapping is useful for the detection of myocardial edema consequent to acute rejection and suggested its use as a novel noninvasive tool for monitoring patients following transplantation. T1 and T2 mapping techniques are also useful for the detection of myocardial edema in patients with stress-related takotsubo cardiomyopathy (23).
CONCLUSION
T1 and T2 mapping are rapidly becoming robust techniques for application in patients with various cardiomyopathies. Currently, T1 and T2 mapping parameters play an important role in clinical decisions. Several studies have reported the efficacies of these techniques for the early and accurate diagnosis of cardiomyopathies. Further studies are required to prove the usefulness of these biomarkers for treatment monitoring and prognosis.
Authors: Marcelo Souto Nacif; Evrim B Turkbey; Neville Gai; Saman Nazarian; Rob J van der Geest; Radwa A Noureldin; Christopher T Sibley; Martin Ugander; Songtao Liu; Andrew E Arai; João A C Lima; David A Bluemke Journal: J Magn Reson Imaging Date: 2011-09-23 Impact factor: 4.813
Authors: Barry J Maron; Jeffrey A Towbin; Gaetano Thiene; Charles Antzelevitch; Domenico Corrado; Donna Arnett; Arthur J Moss; Christine E Seidman; James B Young Journal: Circulation Date: 2006-03-27 Impact factor: 29.690
Authors: William Chan; Stephen J Duffy; David A White; Xiao-Ming Gao; Xiao-Jun Du; Andris H Ellims; Anthony M Dart; Andrew J Taylor Journal: JACC Cardiovasc Imaging Date: 2012-09
Authors: James C C Moon; Bhavesh Sachdev; Andrew G Elkington; William J McKenna; Atul Mehta; Dudley J Pennell; Philip J Leed; Perry M Elliott Journal: Eur Heart J Date: 2003-12 Impact factor: 29.983
Authors: Andrew S Flett; Daniel M Sado; Giovanni Quarta; Mariana Mirabel; Denis Pellerin; Anna S Herrey; Derek J Hausenloy; Cono Ariti; John Yap; Shyam Kolvekar; Andrew M Taylor; James C Moon Journal: Eur Heart J Cardiovasc Imaging Date: 2012-05-25 Impact factor: 6.875
Authors: Stefan K Piechnik; Vanessa M Ferreira; Erica Dall'Armellina; Lowri E Cochlin; Andreas Greiser; Stefan Neubauer; Matthew D Robson Journal: J Cardiovasc Magn Reson Date: 2010-11-19 Impact factor: 5.364
Authors: Kelvin Chow; Peter Kellman; Bruce S Spottiswoode; Sonia Nielles-Vallespin; Andrew E Arai; Michael Salerno; Richard B Thompson Journal: J Cardiovasc Magn Reson Date: 2015-10-01 Impact factor: 5.364
Authors: Sen Ma; Christopher T Nguyen; Fei Han; Nan Wang; Zixin Deng; Nader Binesh; Franklin G Moser; Anthony G Christodoulou; Debiao Li Journal: Magn Reson Med Date: 2019-11-25 Impact factor: 4.668
Authors: Francesco Sardanelli; Simone Schiaffino; Moreno Zanardo; Francesco Secchi; Paola Maria Cannaò; Federico Ambrogi; Giovanni Di Leo Journal: Eur Radiol Date: 2019-05-02 Impact factor: 5.315
Authors: Kathryn E Keenan; Jana G Delfino; Kalina V Jordanova; Megan E Poorman; Prathyush Chirra; Akshay S Chaudhari; Bettina Baessler; Jessica Winfield; Satish E Viswanath; Nandita M deSouza Journal: Med Phys Date: 2021-09-29 Impact factor: 4.506
Authors: El-Sayed H Ibrahim; Luba Frank; Dhiraj Baruah; V Emre Arpinar; Andrew S Nencka; Kevin M Koch; L Tugan Muftuler; Orhan Unal; Jadranka Stojanovska; Jason C Rubenstein; Sherry-Ann Brown; John Charlson; Elizabeth M Gore; Carmen Bergom Journal: Int J Biomed Imaging Date: 2021-05-15
Authors: Ingo Hermann; Peter Kellman; Omer B Demirel; Mehmet Akçakaya; Lothar R Schad; Sebastian Weingärtner Journal: Magn Reson Med Date: 2021-03-29 Impact factor: 4.668